Genetic Technologies Ltd (GENE)
NASDAQ (CM) NASDAQ (CM) Primary Summary
GENE Chart
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
23andMe's Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers
On Sunday, human genetics and biotechnology company 23andMe Holding Co ME voluntarily filed for Chapter 11 bankruptcy to enable a sale process to maximize its business value.
Genetic Technologies Ltd (GENE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Genetic Technologies Ltd ever had a stock split?
Genetic Technologies Ltd Profile
| Professional Services Industry | Industrials Sector | Kevin Camilleri CEO | NASDAQ (CM) Exchange | 37185R406 CUSIP |
| AU Country | 55 Employees | - Last Dividend | 20 Jan 2015 Last Split | 2 Sep 2005 IPO Date |
Overview
Genetic Technologies Limited, established in 1987 and headquartered in Fitzroy, Australia, is a pioneering molecular diagnostics company. With a global reach that spans the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific, the company is dedicated to improving healthcare management through predictive genetic testing and risk assessment tools. It operates through two main segments: EasyDNA and GeneType/Corporate, specializing in genetic testing services across medical, animal, forensic, and plant domains. Genetic Technologies Limited is at the forefront of research and collaboration, partnering with esteemed institutions such as the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom to advance the development of innovative diagnostic solutions.
Products and Services
- BREVAGenplus
A clinically validated risk assessment test for non-hereditary breast cancer, BREVAGenplus is aimed at healthcare professionals in breast health care, imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists such as breast surgeons. This proprietary test provides critical insights for managing the health of individuals at risk of developing breast cancer.
- GeneType for Colorectal Cancer & GeneType for Breast Cancer
These products, marketed under the GeneType brand, offer cancer risk assessment tests specifically for colorectal and breast cancer. Designed to help identify individuals at increased risk of these cancers, the tests support targeted preventive measures and early detection strategies, contributing crucially to personalized healthcare protocols.
- Other Risk Assessment Tests
In addition to its flagship products, Genetic Technologies Limited is actively developing a suite of risk assessment tests across a range of diseases, including colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. These emerging tests represent the company's commitment to expanding its portfolio of predictive genetic testing solutions for various significant health conditions.
- Genetic Testing Services
The company’s scope of services extends beyond human healthcare into diverse fields such as medical, animal, forensic, and plant testing, showcasing its versatility and expertise in genetic diagnostics. These services encompass a broad range of applications, from disease risk prediction and personalized medicine to genetic research in non-human subjects, further highlighting the company's multifaceted approach to genetic testing.
